دورية أكاديمية
أعرض في EDS

ALDOA coordinates PDE3A through the β-catenin/ID3 axis to stimulate cancer metastasis and M2 polarization in lung cancer with EGFR mutations.

التفاصيل البيبلوغرافية
العنوان: ALDOA coordinates PDE3A through the β-catenin/ID3 axis to stimulate cancer metastasis and M2 polarization in lung cancer with EGFR mutations.
المؤلفون: Yeh CY; Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan., Cai HY; Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan., Kuo HH; Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan., Lin YY; Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan., He ZJ; Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan., Cheng HC; Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan., Yang CJ; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan., Huang CF; Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan., Chang YC; Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address: yuchanchang@nycu.edu.tw.
المصدر: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Feb 12; Vol. 696, pp. 149489. Date of Electronic Publication: 2024 Jan 11.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2104 (Electronic) Linking ISSN: 0006291X NLM ISO Abbreviation: Biochem Biophys Res Commun Subsets: MEDLINE
أسماء مطبوعة: Publication: <2002- >: San Diego, CA : Elsevier
Original Publication: New York, Academic Press.
مواضيع طبية MeSH: Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology, Humans ; Fructose-Bisphosphate Aldolase/genetics ; beta Catenin/genetics ; beta Catenin/metabolism ; Signal Transduction/genetics ; Cyclic Nucleotide Phosphodiesterases, Type 3/genetics ; Cyclic Nucleotide Phosphodiesterases, Type 3/metabolism ; Cell Line, Tumor ; Mutation ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Neoplasm Proteins/metabolism ; Inhibitor of Differentiation Proteins/genetics
مستخلص: Lung cancer has a high incidence rate and requires more effective treatment strategies and drug options for clinical patients. EGFR is a common genetic alteration event in lung cancer that affects patient survival and drug strategy. Our study discovered aberrant aldolase A (ALDOA) expression and dysfunction in lung cancer patients with EGFR mutations. In addition to investigating relevant metabolic processes like glucose uptake, lactate production, and ATPase activity, we examined multi-omics profiles (transcriptomics, proteomics, and pull-down assays). It was observed that phosphodiesterase 3A (PDE3A) enzyme and ALDOA exhibit correlation, and furthermore, they impact M2 macrophage polarization through β-catenin and downstream ID3. In addition to demonstrating the aforementioned mechanism of action, our experiments discovered that the PDE3 inhibitor trequinsin has a substantial impact on lung cancer cell lines with EGFR mutants. The trequinsin medication was found to decrease the M2 macrophage polarization status and several cancer phenotypes, in addition to transduction. These findings have potential prognostic and therapeutic applications for clinical patients with EGFR mutation and lung cancer.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
فهرسة مساهمة: Keywords: ALDOA; EGFR mutant; Lung cancer; PDE3; Trequinsin
المشرفين على المادة: EC 4.1.2.13 (Fructose-Bisphosphate Aldolase)
0 (beta Catenin)
EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 3)
EC 2.7.10.1 (ErbB Receptors)
147785-34-0 (ID3 protein, human)
0 (Neoplasm Proteins)
0 (Inhibitor of Differentiation Proteins)
EC 3.1.4.17 (PDE3A protein, human)
EC 2.7.10.1 (EGFR protein, human)
EC 4.1.2.13 (ALDOA protein, human)
تواريخ الأحداث: Date Created: 20240120 Date Completed: 20240202 Latest Revision: 20240202
رمز التحديث: 20240202
DOI: 10.1016/j.bbrc.2024.149489
PMID: 38244313
قاعدة البيانات: MEDLINE
الوصف
تدمد:1090-2104
DOI:10.1016/j.bbrc.2024.149489